Skip to content
Open access

LINC00941 Drives Chemoresistance via Modulating PKM2 Activity and Aerobic Glycolysis in Oral Squamous Cell Carcinoma.

Aug 2026 · Cancer Letters · pp. 218775 · 0 citations · 44 references
Medicine

TL;DR

Findings elucidate a novel lncRNA-dependent pathway governing chemoresistance and propose targeting the LINC00941/PKM2/glycolysis axis as a translatable therapeutic strategy for overcoming CDDP resistance in OSCC.

Abstract

Cisplatin (CDDP) resistance represents a major determinant of poor prognosis in patients with oral squamous cell carcinoma (OSCC). While long non-coding RNAs (lncRNAs) are implicated in chemoresistance pathways, their mechanistic roles in OSCC treatment failure remain incompletely defined. This study identifies LINC00941 as a CDDP resistance-associated lncRNA, with elevated expression correlating significantly with adverse OSCC prognosis. Gain- and loss-of-function assays reveal that LINC00941 overexpression promotes both aerobic glycolysis and CDDP resistance in OSCC cells. Furthermore, elevated LINC00941 expression enhances pyruvate kinase activity, thereby fostering chemoresistance in vitro and in vivo. Mechanistic investigations reveal that LINC00941 physically interacts with pyruvate kinase M2 (PKM2), enhancing its protein stability by suppressing ubiquitin-mediated proteolysis. This stabilization amplifies glycolytic flux, ultimately inducing CDDP resistance in OSCC cells. Our findings elucidate a novel lncRNA-dependent pathway governing chemoresistance and propose targeting the LINC00941/PKM2/glycolysis axis as a translatable therapeutic strategy for overcoming CDDP resistance in OSCC.

Read PDF

Similar papers

Aug 2026

DHCR24+ tumor epithelial cells drive cisplatin resistance in bladder cancer by enhancing cholesterol metabolism to activate lipid raft-associated MAPK signaling

This study characterizes a specific DHCR24+ tumor epithelial subpopulation that orchestrates cisplatin resistance via the "cholesterol-lipid raft-MAPK" axis and establishes a clear mechanistic link between cholesterol metabolism and cisplatin sensitivity.

Yuan-Qiao Zhao, Zhuo Xing, Meng-Meng Wang et al. · 0 citations
Open access Sep 2026

The PKMYT1-ALDOA axis drives chemoresistance in cholangiocarcinoma by enhancing glycolysis and MRE11 lactylation.

Cholangiocarcinoma (CCA) is a highly aggressive biliary malignancy with limited responses to existing treatments. Gemcitabine plus cisplatin (GC) remains the standard first-line chemotherapy for advanced disease, but its clinical efficacy is suboptimal, and drug resistance frequently emerges in patients. Through high-t...

Wei Wu, J. Wang, Wu Yang et al. · 0 citations
Open access Aug 2026

Epigenetically driven GAS2L3 enforces non-canonical cell cycle progression to promote osimertinib resistance in lung adenocarcinoma

These results uncover a metabolism-epigenetics–cell cycle interface that may represent a therapeutic vulnerability in EGFR-mutant LUAD and identify a glycolysis–H4K8la–GAS2L3 axis that drives noncanonical cell-cycle reprogramming independently of classical Cyclin–CDK activation, thereby promoting acquired osimertinib r...

Shu-Man Zhen, Xiaohui Bai, Shu-Tang Liu et al. · 0 citations
Sep 2026

KAT2B epigenetically activates GSTZ1 via H3K9ac to suppress proliferation and stemness and enhance ferroptosis in oral squamous cell carcinoma.

It is found that KAT2B transcriptionally activates GSTZ1 in a H3K9ac-dependent manner, which in turn inhibits GPX4 expression, thereby suppressing OSCC proliferation and stemness while enhancing ferroptosis sensitivity.

Tong Sha, Kun Jiao, Jia-Ning Li et al. · 0 citations
Open access Oct 2026

DKK1 Promotes Cisplatin Resistance in Oral Squamous Cell Carcinoma via SLC3A2‐Dependent Ferroptosis Suppression

ABSTRACT Background Oral squamous cell carcinoma (OSCC) is a prevalent malignancy associated with poor outcomes, largely attributable to cisplatin resistance—the standard chemotherapeutic agent. Aims While ferroptosis has been proposed as a promising therapeutic target, how it is regulated in OSCC remains largely uncle...

Zhuo-Xuan Liu, Xiao-Lang Chen, Yu-Cong Lin et al. · 0 citations
Sep 2026

circMTHFD1L-driven lipid metabolism in Cancer-associated fibroblasts confers oxaliplatin resistance in pancreatic cancer through O-GlcNAcylation-dependent chromatin recruitment of Ku70.

CAF-derived circMTHFD1L drives oxaliplatin resistance in PDAC by stabilizing ACC1 to reprogram FA metabolism and promote Ku70 O-GlcNAcylation, identifying the circMTHFD1L/ACC1/Ku70 axis as a promising target to overcome chemoresistance.

Qing Tian, Tian-Hao Huang, Ning-Ning Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.